12-year results of the phase III SOFT trial show a maintained disease-free survival benefit
12-year results of the phase III SOFT trial show a maintained disease-free survival benefit
top of page
Latest News
Search
Alamo Breast Cancer
- Jul 29, 2021
- 2 min
This KEYTRUDA Combination Is Approved for High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
This KEYTRUDA Combination Is the First Immunotherapy Regimen Approved for High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
43 views0 comments
Alamo Breast Cancer
- Apr 28, 2020
- 0 min
New COVID-19 Resources from FORCE
Information about the COVID-19 pandemic for people diagnosed with, or at high risk for, ovarian/endometrial cancer
47 views0 comments
-
- Jan 22, 2020
- 2 min
Over 20 Years Fighting For Those Who Came Before and Those Who Will Come After
Working with the foundation entails many rewarding experiences and Sandi keeps her fondest memories with ABCF close to her heart.
218 views0 comments
We Need Your Support Today!
bottom of page